Press Releases:

BD Announces Acquisition of Atto Bioscience, Inc.
San Jose, CA, July 1, 2004 - BD (Becton, Dickinson and Company) (NYSE: BDX), through its BD Biosciences segment, today announced that it has acquired Atto Bioscience, Inc. in a cash transaction valued at approximately $25 million. >>more

Atto Bioscience Signs Agreement to Acquire Cytoprint, Inc.
Rockville, MD - September 10, 2003 - Atto Bioscience, Inc. today announced that it has signed a definitive agreement to acquire Cytoprint, Inc. in a cash and stock transaction projected to close by October 31, 2003. >>more

Atto Bioscience Launches Biosensor Technology for GPCR Drug Screening
Rockville, MD - September 11, 2003 - Atto Bioscience, Inc. today announced the launch of ACT:One™, a proprietary live-cell technology for G-protein coupled receptor (GPCR) drug discovery. >>more

Atto Bioscience Launches ACT:One™ Novel GPCR cAMP Biosensor Technology
Rockville, MD - Atto Bioscience announces the launch of ACT:One™ a new technology for GPCR drug discovery. >>more

Atto Bioscience, Inc. Raises $3 million in First Round of Equity Financing
Rockville, MD - October 29, 2001 - Atto BioScience, Inc. announces that it has completed its first round of equity financing, raising $3 million from investors led by Emerging Technology Partners, LLC , along with other individuals from the biotech community, company founders and management >>more

Atto Bioscience Appoints Kinetic Imaging as CARV® dealer in Europe and Southeast US
Rockville, MD - Atto Bioscience announces the appointment of Kinetic Imaging as a co-exclusive distributor of Atto's CARV® confocal technology in Europe and Southeastern United States. >>more

Atto signs dealership agreements for nationwide distribution of its full spectrum live-cell CARV® confocal module
Rockville, MD - In an effort to expand it's nationwide presence in the personal confocal market, Atto Bioscience announced Friday that it has completed agreements with a number of well respected microscope dealers, providing market coverage to the entire United States. >>more

Atto Bioscience Awarded $600,000 DARPA Project to Develop Olfactory Receptor-Based Biosensors
Rockville, MD - Atto Bioscience announced today that it has received a $600,000- award from the Defense Advanced Research Agency (DARPA) to apply its proprietary automated confocal imaging platform (Pathway HT™), and expertise in high-throughput cloning, protein expression and genome engineering to develop olfactory receptor-based biosensors for real-time detection of agents of interest to the Department of Defense. >>more